How Medicare’s New Drug Price Negotiation Program Could Expand Access to Selected Drugs September 26, 2023 Issue Brief This brief examines how Part D enrollees’ access to and utilization of the first set of 10 selected drugs could be affected by the new Part D coverage and formulary requirements for selected drugs established by the Inflation Reduction Act and in CMS guidance, as well as the potential for lower out-of-pocket costs.
What are the recent and forecasted trends in prescription drug spending? September 15, 2023 Slideshow
The 4 Arguments You Will Hear Against Drug Price Negotiation September 6, 2023 Perspective As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF’s Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
Will Where You Live Determine Access and Coverage of Emerging Anti-Obesity Drugs? August 30, 2023 Blog The U.S. Midwest and South regions have higher average obesity rates among adults. What does this mean for access and coverage of prescription drugs for weight loss?
Understanding Mergers Between Hospitals and Health Systems in Different Markets August 23, 2023 Issue Brief This brief explains the role and implications of cross-market mergers between hospitals and health systems that operate in different regions and describes the approaches that government antitrust agencies have taken in reviewing these types of transactions.
Public Opinion on Prescription Drugs and Their Prices August 21, 2023 Poll Finding This chart collection draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.
Drugs Used for Weight Loss Could Cost Americans Much More Than People in Peer Countries August 17, 2023 News Release In addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs. Ozempic, which has been approved in the…
How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices? August 17, 2023 Issue Brief A class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment. A new analysis compares list prices for…
Understanding the Role of the FTC, DOJ, and States in Challenging Anticompetitive Practices Of Hospitals and Other Health Care Providers August 7, 2023 Issue Brief This brief explains the role of federal and state antitrust agencies in challenging anticompetitive practices among hospitals and other health care providers, including the legal authority of federal and state agencies, the role that they play in enforcing antitrust laws, and proposed options for strengthening their authority.
Marketplace Insurers are Proposing a 6% Average Premium Hike for 2024 and Pointing to Inflation as a Key Driver of Costs August 4, 2023 News Release ACA Marketplace insurers are requesting a median premium increase of 6% for 2024, according to a new KFF analysis of the preliminary rate filings. Insurers’ proposed rate changes – most of which fall between 2% and 10% – may change during the review process. Although most Marketplace enrollees receive subsidies…